摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-[3-(1-phenyl-1 H-tetrazol-5-ylsulfonyl)propyl]octanethioate | 1196806-30-0

中文名称
——
中文别名
——
英文名称
5-[3-(1-phenyl-1 H-tetrazol-5-ylsulfonyl)propyl]octanethioate
英文别名
S-[3-(1-phenyltetrazol-5-yl)sulfonylpropyl] octanethioate
5-[3-(1-phenyl-1 H-tetrazol-5-ylsulfonyl)propyl]octanethioate化学式
CAS
1196806-30-0
化学式
C18H26N4O3S2
mdl
——
分子量
410.561
InChiKey
NEKLNWPZLQGLEK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    580.4±52.0 °C(predicted)
  • 密度:
    1.27±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    27
  • 可旋转键数:
    13
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    129
  • 氢给体数:
    0
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Total Synthesis of Largazole - Devolution of a Novel Synthetic Strategy
    作者:Craig Forsyth、Bo Wang
    DOI:10.1055/s-0029-1216931
    日期:2009.9
    largazole embodies a compelling combination of a relatively simple, yet unique cyclic depsipeptide structure with remarkable levels of selective cytotoxicity against cancer cell lines versus nontransformed cells. The unique structure of largazole inspired a strategically novel and aggressive approach towards its expedient total synthesis. This involved an initial dissection into an epoxy aldehyde and an unprotected
    蓝细菌分离物拉格唑体现了相对简单而独特的环状双缩肽结构的令人信服的组合,该结构具有显着水平的针对癌细胞系和未转化细胞的选择性细胞毒性。largazole的独特结构激发了一种战略上新颖且具有侵略性的方法来实现方便的全合成。这涉及到初始分解为环氧醛和未保护的四肽,分别代表拉格唑的聚酮和多肽结构域。这些片段使用NHC介导的酰胺化成功连接,但随后通过内酯化的环状二肽的组装受到阻碍。关键联轴器的重新排序导致了largazole的成功组装。 全合成-杂环-十肽-N-杂环卡宾-噻唑啉
  • Total Syntheses of the Histone Deacetylase Inhibitors Largazole and 2-<i>epi</i>-Largazole: Application of <i>N</i>-Heterocyclic Carbene Mediated Acylations in Complex Molecule Synthesis
    作者:Bo Wang、Po-Hsien Huang、Ching-Shih Chen、Craig J. Forsyth
    DOI:10.1021/jo102478x
    日期:2011.2.18
    Details of the evolution of strategies toward convergent assembly of the histone deacetylase inhibiting natural product largazole exploiting gamma,delta-unsaturated-alpha,beta-epoxy-aldehydes and a thiazole-thiazoline containing omega-amino-acid are described. The initial N-heterocyclic carbene mediated redox amidation exploying these two types of building blocks representing largazole's structural domains of distinct biosynthetic origin directly afforded the seco-acid of largazole. This was accomplished without any protecting groups resident upon either thioester bearing epoxy-aldehyde or the tetrapeptide. However, the ineffective production of largazole via the final macrolactonization led to an alternative intramolecular esterification/macrolactamization strategy employing the established two building blocks. This provided largazole along with its C2-epimer via an unexpected inversion of the alpha-stereocenter at the valine residue. The biological evaluation demonstrated that both largazole and 2-epi-largazole led to dose-dependent increases of acetylation of histone H3, indicating their potencies as class I histone deacetylase selective inhibitiors. Enhanced p21 expression was also induced by largazole and its C2 epimer. In addition, 2-epi-largazole displayed more potent activity than largazole in cell viability assays against PC-3 and LNCaP prostate cancer cell lines.
  • Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities
    作者:Yiwu Yao、Zhengchao Tu、Chenzhong Liao、Zhen Wang、Shang Li、Hequan Yao、Zheng Li、Sheng Jiang
    DOI:10.1021/acs.jmedchem.5b01044
    日期:2015.10.8
    exhibit promising antiproliferative activities in the nanomolar range against various cancer cell lines. Compounds 12 and 13 show more than 20-fold selectivity toward human cancer cells over human normal cells in comparison with romidepsin (FK228), demonstrating low probability of toxic side effects. In addition, compound 13 exhibits excellent in vivo anticancer activities in a human prostate carcinoma (Du145)
    描述了一种成功的基于环状结构的新型环状二肽,其选择性靶向I类HDAC同工型。化合物11具有2.78 nM的IC 50,可与HDAC1蛋白结合,并且前药12和13在纳摩尔范围内还具有针对各种癌细胞系的有希望的抗增殖活性。与罗米地辛(FK228)相比,化合物12和13对人癌细胞的选择性超过人正常细胞的20倍以上,这表明毒性副作用的可能性较低。另外,化合物13在人前列腺癌(Du145)异种移植模型中显示出优异的体内抗癌活性,没有观察到毒性。因此,前药13具有作为用于进一步临床翻译的新型抗癌剂的治疗潜力。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺